NAFLD & MASLD
Peptides explored for NAFLD and MASLD — semaglutide, tirzepatide, survodutide, retatrutide, MOTS-c — with mechanism, evidence from biopsy-controlled trials, and how peptide therapy fits the rapidly evolving fatty liver treatment landscape.
Non-alcoholic fatty liver disease — recently renamed to MASLD (metabolic dysfunction-associated steatotic liver disease) to better reflect the underlying metabolic etiology — affects approximately 25–30% of adults globally and is now the most common cause of chronic liver disease in developed countries. The clinical spectrum runs from simple steatosis (fat accumulation alone) through MASH (steatohepatitis with inflammation and hepatocellular injury) to fibrosis and cirrhosis. The progressive subset — roughly 20% of MASLD patients — develop fibrosis that drives liver-related and overall mortality.
Until 2024, no FDA-approved drug existed for MASLD or MASH. Lifestyle modification (weight loss of 5–10% reverses steatosis in most patients; 10%+ reverses some fibrosis) has remained the foundation. The landscape changed dramatically with resmetirom (Rezdiffra, a thyroid hormone receptor-β agonist) becoming the first FDA-approved MASH therapy in March 2024, and with the subsequent demonstration that GLP-1 receptor agonists and GLP-1/glucagon dual agonists produce meaningful improvements in liver fat, hepatic inflammation, and (in some agents) fibrosis. Peptide therapy is now central to the modern MASLD/MASH treatment conversation.
The peptides most relevant to fatty liver — semaglutide, tirzepatide, survodutide, retatrutide, mazdutide, pemvidutide, MOTS-c — converge on overlapping mechanisms: weight loss (fundamental driver of steatosis improvement), glucose-lipid metabolism normalization, hepatic insulin sensitization, and (for glucagon-receptor-active agents like survodutide, retatrutide, and pemvidutide) direct hepatic fat oxidation through glucagon receptor agonism. The combined effect is one of the most active areas of late-stage drug development in modern hepatology.
This page covers what's actually known about peptides for MASLD/MASH, where the evidence is strongest, how peptide therapy fits alongside lifestyle intervention, and important caveats. It is informational, not medical advice.
Peptides discussed for NAFLD & MASLD
Semaglutide
GLP-1 Receptor Agonist
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist
A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Dulaglutide
GLP-1 Receptor Agonist
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes, with proven cardiovascular benefits and moderate weight loss effects.
Liraglutide
GLP-1 Receptor Agonist
A GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.
Retatrutide
Triple GIP/GLP-1/Glucagon Receptor Agonist
An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.
Survodutide
Dual Glucagon/GLP-1 Receptor Agonist
An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.
Exenatide
GLP-1 Receptor Agonist
The first GLP-1 receptor agonist, originally derived from Gila monster venom, FDA-approved for type 2 diabetes.
FGF21
Hepatokine
The hepatic peptide hormone of fasting and ketogenic states — and the target behind the most exciting current NASH/MASH pipeline. Native FGF21 has a half-life measured in hours; the clinical drugs are engineered Fc-fusions and PEGylated variants dosed weekly.
Mazdutide
Incretin Mimetic
The world's first approved dual GLP-1/glucagon receptor agonist, developed by Innovent Biologics (China). Approved in China for obesity and type 2 diabetes. Phase 3 trials showed up to 20.1% weight loss.
MOTS-c
Mitochondrial Peptide
A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'
How peptides target nafld & masld
Three mechanistic axes drive peptide therapy interest in fatty liver disease. First and most powerful: weight loss. Sustained 5–10% body weight reduction reverses hepatic steatosis in the majority of patients, and 10%+ reverses some fibrosis. GLP-1 agonists and GLP-1/GIP dual agonists (tirzepatide) produce 10–25% body weight reductions in patients with obesity, translating to substantial hepatic fat reduction in observational and dedicated MASLD trials. Weight loss alone explains a large fraction of the GLP-1 class effect on the liver.
Second, GLP-1 agonism has direct hepatic effects beyond weight loss. GLP-1 receptors are expressed at low levels on hepatic stellate cells and Kupffer cells; the agonists modulate hepatic insulin sensitivity, reduce hepatic de novo lipogenesis, decrease pro-inflammatory cytokine signaling, and may directly modulate fibrogenic activity. Whether these effects are independent of weight loss is contested — most analyses suggest that the bulk of liver benefit tracks weight loss, with modest additional weight-independent contribution.
Third, glucagon receptor agonism (added in survodutide, retatrutide, pemvidutide, and the China-approved mazdutide) drives direct hepatic fat oxidation. Glucagon's classical hepatic actions — glycogenolysis, gluconeogenesis, lipid oxidation — produce marked reductions in hepatic triglyceride content when chronically activated at controlled levels. The Pemvidutide MASLD trial (2024) and the survodutide SYNCHRONIZE trials specifically demonstrated this mechanism in MASLD patients, with hepatic fat reductions exceeding what weight loss alone would predict.
MOTS-c has a separate mechanistic angle — mitochondrial peptide signaling that activates AMPK, improves hepatic insulin sensitivity, and shifts hepatic energy metabolism. Preclinical data in MASLD mouse models is promising; human translation is limited.
What the evidence shows
The evidence base has expanded rapidly in the last 3 years. Semaglutide produced significant MASH resolution in a Phase II biopsy-controlled trial (Newsome et al. NEJM 2021), with 59% of patients on 0.4 mg daily semaglutide achieving MASH resolution versus 17% on placebo. Fibrosis improvement was less consistent, raising questions about whether weight-loss-driven steatosis reversal translates fully to fibrosis regression in shorter trial windows. The Phase III ESSENCE trial in MASH is ongoing.
Tirzepatide demonstrated significant hepatic fat reductions in Phase II MASLD/T2D trials, with the proportional reductions exceeding semaglutide based on indirect comparisons — consistent with tirzepatide's larger overall weight loss effect. Dedicated Phase III MASH outcomes data is accruing.
Survodutide (GLP-1/glucagon dual agonist) demonstrated 83% MASH resolution and 64% fibrosis improvement at 48 weeks in a 2024 Phase II MASH trial — the strongest fibrosis signal seen with any peptide to date, plausibly driven by the glucagon-receptor-mediated direct hepatic fat oxidation. The SYNCHRONIZE Phase III program is establishing pivotal evidence for MASLD/MASH approval.
Retatrutide (GLP-1/GIP/glucagon triple agonist) produced ~15–25% body weight loss in Phase II obesity trials, with retrospective analysis showing substantial hepatic fat reductions. Dedicated MASLD trials are running.
Pemvidutide (GLP-1/glucagon dual) demonstrated meaningful MASLD-specific outcomes in a 2024 randomized trial. Mazdutide (China-approved GLP-1/glucagon dual) showed reductions in liver enzymes and hepatic fat in its T2D and obesity trials.
Resmetirom (Rezdiffra) is not a peptide but is now FDA-approved for non-cirrhotic MASH with significant fibrosis (March 2024) — the first approved MASH drug, providing a small-molecule option that does not require weight loss as a mechanism. Resmetirom plus a GLP-1 agonist combination is an active clinical question.
MOTS-c has preclinical MASLD data only. No published Phase 2 trials exist as of 2026.
What to expect
Outcomes depend heavily on disease stage, weight loss achieved, and which agent is used. With semaglutide 2.4 mg weekly in MASLD with obesity: typical body weight loss of 12–15% with proportional liver fat reduction over 12–18 months, and meaningful MASH resolution rates in biopsied patients. Fibrosis improvement is more variable and slower.
With tirzepatide: typically larger weight loss (15–22%) with corresponding larger hepatic fat improvements, on a similar timeline. With survodutide or retatrutide (both not yet FDA-approved in the West as of mid-2026): trial data suggests larger fibrosis benefit driven by the glucagon-receptor mechanism, but real-world experience is limited.
Elevated liver enzymes (ALT, AST) typically improve within 8–12 weeks. Hepatic fat (measured by MRI-PDFF) improves over 6–12 months. Histologic improvements in MASH and fibrosis take longer (12–24 months minimum) and require biopsy or non-invasive equivalents (FibroScan, ELF) to track.
What to NOT expect: replacement of lifestyle modification (weight loss, dietary improvement, alcohol reduction, exercise) — peptide therapy enhances rather than replaces these foundations. Reversal of established cirrhosis (compensated or decompensated cirrhosis is a different clinical entity that requires hepatology specialty care). Independence from monitoring: liver enzymes, lipid panel, and (for advanced fibrosis) fibrosis assessment require ongoing follow-up.
Important caveats
MASLD/MASH management should be directed by a hepatologist or experienced gastroenterologist, particularly for patients with advanced fibrosis (F2 or higher) or cirrhosis. Patients with cirrhosis face different considerations including hepatic decompensation risk, hepatocellular carcinoma surveillance, and portal hypertension management — these require specialty hepatology care.
GLP-1 agonists carry the same class precautions in MASLD patients as in any other indication: medullary thyroid carcinoma boxed warning (contraindicated in MTC and MEN2 history), pancreatitis risk (rare but real), gallbladder disease (modestly elevated risk), and gastrointestinal side effects requiring slow titration. Patients with significant gastroparesis are not good candidates.
Weight loss interventions in patients with cirrhosis or advanced fibrosis require careful management — rapid weight loss can worsen sarcopenia and frailty, particularly in cirrhotic patients with already-impaired protein synthesis. Combination of GLP-1 therapy with adequate protein intake and resistance training is increasingly recommended.
Resmetirom (Rezdiffra) is the only FDA-approved MASH-specific drug; it is not a peptide. Its combination with GLP-1 agonists is an active clinical question without definitive RCT guidance yet.
Compounded GLP-1 products carry the same caveats as in any other indication. The FDA removed semaglutide and tirzepatide from the drug-shortage list in 2024–2025, narrowing the legitimate compounding window.
Frequently asked questions
Which peptide is best for fatty liver?
It depends on disease stage and goals. For most MASLD/MASH patients with obesity or T2D, semaglutide or tirzepatide produce the largest weight loss and substantial hepatic fat reduction. For patients with significant fibrosis, GLP-1/glucagon dual agonists (survodutide, retatrutide, pemvidutide) showed the strongest fibrosis-improvement signals in Phase 2 — survodutide in particular reported 64% fibrosis improvement at 48 weeks. None of these dual agonists is yet FDA-approved in the West for MASLD specifically. The right choice should be made with a hepatologist based on disease stage and other comorbidities.
Can semaglutide reverse fatty liver?
Yes, often. Semaglutide produces substantial liver fat reduction proportional to its weight loss effect — 12–15% body weight loss typically corresponds to 30–60% hepatic fat reduction by MRI-PDFF. The Newsome 2021 NEJM trial demonstrated MASH resolution in 59% of patients on 0.4 mg daily semaglutide versus 17% on placebo. Fibrosis improvement is more variable. The Phase 3 ESSENCE trial is establishing pivotal data for MASH approval.
Is MOTS-c proven for fatty liver?
No. MOTS-c has preclinical evidence in mouse MASLD models — improved hepatic insulin sensitivity, reduced steatosis, AMPK activation. Human MASLD trials have not been published. MOTS-c's mechanism aligns with the metabolic pathology of MASLD, but clinical translation is unproven. Use is research-chemical territory with no FDA approval and unverified product identity across vendors.
What about resmetirom — should I take that instead of a peptide?
Resmetirom (Rezdiffra) became the first FDA-approved drug specifically for non-cirrhotic MASH with significant fibrosis in March 2024. It is a thyroid hormone receptor-β agonist — a small molecule, not a peptide — and works through hepatic fat metabolism without requiring weight loss. It can be used alongside GLP-1 agonists, and the combination is an active clinical question. For patients with substantial obesity, GLP-1 therapy may be preferable as the foundation (driving large weight loss with hepatic benefit); for patients with relatively normal weight but significant MASH/fibrosis, resmetirom may be the more direct choice. Hepatology consultation is appropriate for individualized recommendations.
How long does it take peptides to improve fatty liver?
Liver enzymes (ALT, AST) typically improve within 8–12 weeks of starting a GLP-1 agonist. Hepatic fat (MRI-PDFF) improves over 6–12 months proportional to weight loss. Histologic improvements in MASH and fibrosis are slower — 12–24 months minimum — and require biopsy or non-invasive fibrosis assessment to track. Patients should expect peptide-driven liver improvement to be a months-to-years timeline, not weeks.
Do I still need to lose weight if I'm on a GLP-1 for fatty liver?
The GLP-1 agonist will produce substantial weight loss as part of its mechanism — that weight loss is the primary driver of hepatic fat reduction. You don't need to add separate weight-loss interventions on top, but lifestyle support (adequate protein, exercise, alcohol reduction, dietary improvement) optimizes the response and protects lean mass during weight loss. The peptide is the engine; lifestyle is the framework that makes the engine work as well as possible.
Part of these goals
Related conditions
Peptide families relevant to NAFLD & MASLD
Stacks that overlap
- CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)
A family of weekly injectable obesity stacks that pair the long-acting amylin analog cagrilintide with a GLP-1 receptor agonist — semaglutide (CagriSema), tirzepatide (CagriTriz), or retatrutide (CagriReta). Only CagriSema has completed pivotal clinical trials; the other two are conceptual compounded or investigational combinations.
Updated 2026-05-08